Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Hello and a warm welcome to everyone for joining BICO AB's earnings call for quarter one 2024. My name is Maria Forss and I'm the CEO and president of BICO AB. And together with our CFO, Jacob Thordenberg, I will present our report for the first quarter of 2024. Let's review today's agenda. Our agenda is divided into five sections before the Q&A section. We will give you a summary of the quarter, highlight significant events from the past quarter, and brief you on the communication yesterday about the change in the method for the impairment test of goodwill, resulting in retroactive impairment of goodwill and other intangible assets. We'll give a brief comment on the market development and outlook, and thereafter present our financial performance for the quarter, as well as how our business areas performed during quarter one. This section will be in listening-only mode. After the presentation, we will move to the Q&A where you can participate and ask questions. The operator will be back with further instructions. This section will be a little more extended for this quarter. And if we take a brief overview of the quarter, it's pleasing to see that we improved our organic growth. However, the mixed performance impacted our profitability. We continue to see slower sales in both academia and diagnostics, and this hampered both sales levels as well as profitability. Our group will comment more on the numbers in the financial section, so I will just conclude on a high level. I will brief you on the strategic review of our current R&D projects and the group product portfolio. This is work that we carry out in preparation for the launch of our updated strategy later this year. I will also brief you on the whistleblower investigation, which we communicated back in March. Our group will inform you about the discussions with the Council for Swedish Financial Reporting Supervision and the retroactive impairment of goodwill and other intangible assets announced yesterday evening. But before that, I would like to spend a minute on presenting our latest additions to the executive management, Katharina Nordland and Anders. We welcomed Katharina in April and Anders will join us mid-June. So yes, those events took place after quarter one, but I think it's worth mentioning during this call, Katharina, our new Chief Human Resources Officer, and her focus will be to enable, shape, and execute BICO AB's global HR strategy to build a people-focused and high-performance culture. And as for Anders, our new Chief Commercial Officer, his main responsibilities will be to scale the BICO business, increasing the commercialization efforts of the portfolio and further exploring opportunities for collaborations and partnerships. They are both great additions to our management team and important cornerstones. When we are reinforcing both investment in people and culture and our increased commercial focus. The conclusions from the whistleblower investigation conducted by an external party at the request of the board of directors were communicated in March. Three aspects should be underlined. First, the whistleblower report refers to historical events from 2017 to 2021. Secondly, the report has not been able to show any criminal act. And third and last, it doesn't lead to any further accounting measures. They work with strengthening. Our internal control systems have been in place since 2022, and we will continue to make sure that we stay proactive, as well as fostering and developing the right business culture. I will now hand over to Jacob for a summary about the impairment of goodwill and other intangible assets.
Thank you, Bruno. Uh, this information was released yesterday evening, Central European Time. Since we resolved on a change of method for impairment tests of goodwill resulting in retroactive impairment of goodwill and other intangible assets for 2022 and 2023. It is important to mention that these adjustments are all non-cash flow items and will not impact Q1 2024 figures negatively. The impairment follows discussions with the Council for Swedish Financial Reporting Supervision regarding impairment tests of goodwill made by BICO AB in 2022 and 2023. The council has, as part of the normal oversight of listed companies, reviewed BICO AB's annual report for 2022 and more precisely, the impairment tests of goodwill, according to IAS 36. We have had a good and constructive dialogue with the Council, where they have advocated that BICO AB should use a five-year forecast period instead of a ten-year model as the ten-year model. According to IAS 36, a ten-year forecast period can only be motivated if underpinned with high forecasting accuracy beyond year five. As disclosed in our annual reports, BICO AB has historically, in its impairment tests, applied a forecast period of ten years. This chosen period of ten years, which has been audited and accepted in our annual reports for 2022 and 2023, was used to reflect what BICO AB believes to be the right value of the businesses, given its growth prospects. It should be noted that BICO AB made changes to the length of the period used in impairment tests as instructed by the Council, from ten to five years. All other parameters such as projections and discount rates have remained unchanged. I will now brief you on the retroactive financial effects on the balance sheet and the profit and loss statements. If we begin with the P&L. When applying the five-year forecast period, it has the following EBIT effect. For 2022, it will be -2,574,000,000, and then a positive effect of 785,000,000 in 2023. The reason for this is that the new forecast period of five years results in a larger historical impairment in 2022 and less impairment in 2023, as previous goodwill impairments made in 2023 were shifted to 2022. And if we go to the next slide and look at the balance sheet. Uh, this is a rather busy slide, but here you see previously reported adjustments and adjusted reported per year end 2022 and 2023 for intangible assets, including goodwill. We have the following: Retroactive change decreased intangible assets with -2,668,000,000 as per year end 2022 compared to the previously reported balance. The corresponding effect as per year end 2023 was -1,838,000,000. Second highlighted item total equity, where the retroactive change has decreased equity with 2,663,000,000 as per year end 2022 compared to the previously reported balance. The corresponding effect as per year end 2023 was -1,808,000,000, and the final box deferred tax liabilities decreased by -5 million as per year end 2022 compared to the previously reported balance. The corresponding effect, as for year end 2023 was -30 million. In total, the goodwill value per year end 2023 has decreased by 1,736,000,000. Detailed information can also be found in note ten in our Q1 report. Back to you, Maria.
Thank you. As previously communicated, the review consists of an assessment of the current R&D projects and the group's product portfolio. This work is carried out in preparation before launching the updated strategy. The Project Management Office in BICO is working with the review of R&D projects across the group, and an R&D board has also been established where key projects will be reviewed by executive management, ensuring focused and customer insight-driven R&D investments. Due to the heavy dependency on academia and the diagnostic sectors where the business has been soft for some time, there are certain measures being made in our operating companies selling in cyan. For selling. A new management is in place and measures have been concluded in two specific areas: the commercial offering and cost savings. The commercial offering will be focusing on the core portfolio, and a new strategy has also been implemented to ensure profitable growth. In terms of cost savings, we target savings of 20 million.
For.
Quarter one has concluded that there was a need for writedowns of capitalized R&D and selling of 85 million, which impacted EBIT for sale. And we are continuing to actively work with restructuring and reshaping of the business, both from an offering and cost perspective. A new commercial lead is in place and in terms of cost savings, we are targeting €1.5 million. This was the last slide of the summary of quarter one, so I will move into the next section and comment on market development and outlook. This is a new section where I will give some more flavor on the market development and outlook, as well as commenting on sales per geography. I believe that we see the same trends and patterns as our peers have reported in quarter one. The indications are that the slower businesses in academia and diagnostic segments continued during quarter one this year. We also saw geographical differences in demand, where sales in North America and Europe are beginning to show positive signs, whereas Asia remains softer. As you can see, our sales were strong in North America and this can mainly be explained by strong sales from biosciences. Europe is performing within the same range as the corresponding quarter last year, as well as the rest of the world. We do see, though, that Asia performed weakly in quarter one, and this was primarily attributable to selling in cyan. I will now hand over to Jacob again for a summary of our financial performance.
Thank you, Brian. I will now summarize the first quarter of 2024. All numbers presented are in Swedish crowns except when otherwise stated. Furthermore, this is also the first quarter where BICO reports in functional reporting and all organic growth figures are in constant currency. BICO delivered sales of 510 million with an organic growth of 5% in the quarter. Adjusted EBITDA amounted to -9 million and EBITDA was -19 million, impacted by the software business in bioprinting and by automation. As previously communicated, this is the first quarter whereby BICO applied functional reporting and comparable numbers have been adjusted. The reason for this is to increase comparability in the company's cost structure and adapt to the most common market practice. The change has affected the reported gross margin negatively as more costs than before, For example, production cost, depreciation on production equipment, etc., have been included in reported cost of goods sold instead of OpEx. The gross margin for the quarter amounted to 45%, which was seven percentage points lower than the corresponding quarter last year. This is explained by the product mix with more revenue from CELLINK with a different gross margin profile compared to our instrument companies, which included more costs in COGS due to its project business, as well as lower sales in bioprinting and bioscience, resulting in less economies of scale on production staff, etc. The net loss for the quarter amounted to -29 million, and if we delve into our net sales for the first quarter, the sales amounted to 510 million, as mentioned, with a total sales growth of 4%. Our business areas delivered mixed sales performance where Biosciences delivered robust sales levels. Historically, Q1 is normally a seasonally weak quarter, and this was no exception for the bioprinting and bioautomation businesses with breakthrough developments in selling and science. It was, however, pleasing to see strong sales levels in bioscience. The indication of slower business in the academia and diagnostic segment continued during Q1 2024. We also saw geographical differences in demand, where sales in North America and Europe began to show positive signs, whereas Asia remains softer; moving on to profitability. Adjusted EBITDA for Q1 amounted to -9 million, corresponding to a margin of -2%. Softer business in bioprinting and bioautomation, primarily in selling and science had a negative impact, which was offset by the strong sales in bioscience. Staying on course with cost control for the group has been guiding for the quarter and will continue to be a focus during the quarters to come. And if we move on to cash flow, cash flow from operating activities for the quarter amounted to -17 million, impacted by the financial performance in the quarter. This also includes a positive effect from changes in working capital of 27 million. Out of this, decrease in operating receivables amounted to 163 million. This is primarily related to accounts receivable being collected in Q1, following our seasonally high sales in Q4. Inventories decreased by 22 million, continuing the trend of decreasing inventory levels as also seen in Q4 2023. Cash flow from changes in operating liabilities amounted to -158 million, primarily related to supplier payments connected to sales in Q4 2023 and contract liabilities converted to revenues. Investments in intangible CapEx amounted to $8 million, and several R&D projects were completed in the second half of 2023, resulting in a reduction in capitalized R&D. Investments in tangible CapEx also amounted to 8 million. Earnout payments amounted to $28 million in the quarter, and the total estimated remaining earnout payments amount to $20 million. Total cash flow during Q1 amounted to -77 million, and cash reserves by the end of March 2024 amounted to 796 million. On this slide, I will further elaborate on working capital improvements during the last quarters. Please note that all working capital numbers are excluding. Between Q1 2023 and Q1 2024. Net working capital decreased from 608 million to 463 million. The main drivers for this development include accounts receivable improvements, which decreased from 442 million to 362 million, an improvement by 80 million, explained by more robust processes including better collection and payment processes, as well as group guidance. Inventories decreased from 506 million to 414 million, an improvement of 92 million. More stringent processes and agreements in place have managed to stop further increases in 2023, and we expect to continue seeing decreasing effects throughout 2024. Working capital liabilities increased modestly by 26 million. Total improvements amounted to 145 million, or a decrease from around 33 to 21% of net working capital in relation to the last 12 months' sales. Maria will now comment on our business areas' performance.
Yes, I will guide you through our business areas for the first quarter. The bioprinting business area reported net sales of 113 million in the first quarter. The organic growth in the segment was -21% and the adjusted EBITDA was -21 million, corresponding to a margin of -19%. The business area reported significantly weaker sales compared to the corresponding quarter last year, and the lower sales levels can be explained by a softer market as well as redundant sales efforts. Measures have been concluded in two specific areas: commercial offering and cost savings, as mentioned earlier in this call. Moving on to our next business area, Biosciences. In the first quarter, the business areas. Net sales amounted to 313 million. The organic growth was 36% and the adjusted EBITDA was 35 million, corresponding to a margin of 11%. Biosciences delivered strong sales levels compared with the corresponding quarter last year, and was also affected by the project effect on the business. The significantly stronger sales, as well as continuous cost control, contribute to the positive development in EBITDA margins. Our third business area, Automation, reported in the first quarter net sales of 84 million. The organic growth for the quarter was -27% and adjusted EBITDA amounted to 6 million, corresponding to a margin of 7%. The business area's sales growth was negative compared to the corresponding quarter last year, with sales levels still hampered by weak demand from the diagnostic industry. The profitability for the quarter was negatively impacted by ongoing restructuring, and we're continuing to actively work on reshaping the business, both from an offering and a cost perspective. The Finnish group company Generalist was divested in November 2023 and has been treated as discontinued operations from Q4 2023. With that being said, it's time to open up for our Q&A. Please follow the instructions from the financial hearing host.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Rickard Krantz from Handelsbanken. Please go ahead.
Good morning, and thank you for taking my questions. So, I have a few questions. So first, could you elaborate a bit on the weaker gross margin; perhaps you could provide more commentary in detail around the gross margin contribution, how we should think about that for the BioConvergence business, which seems to be pushing down the gross margin, and should we then expect similar gross margin levels in quarters to come, given the quite significant decline year over year? I guess that would be helpful to understand the trajectory of the gross margin for the full year. Thank you.
Sure. Good question. Yes, as we.
Said, the.
Gross margin decreased by seven percentage units quarter over quarter. And this was primarily explained by Sheridan. And the reason for this is that BioSphere has a different gross margin profile than our other instrument companies. And that is that it's a project business. In a project business, you allocate more costs to specific projects. But the consequence of that is that you have less OpEx. So you have an even more fully loaded COGS in a project-based business such as BioSphere. So, going forward,
Um.
Any dilution of our margin, you could expect a dilution from our margin if you expect BioSphere to continue to grow. And we do see strong underlying growth in terms of lab automation.
All right. Thank you. And I noticed also that consumable sales were down year over year. Um, could you elaborate why that is? And if we should anticipate similar softness in the consumables development and maybe if you could square that also with the sort of installed base and how that's been growing. Thank you.
Um, yes.
The decline that we're seeing in consumables is related to what Maria and I commented on, related to SCIENION and CELLINK, which had weaker sales in Q1, and that also includes sales of consumables.
All right. Uh, but how should we think about the other business areas in terms of consumable pull through and the momentum there?
I think the way you should see it, we had this question also in the last quarter call, and that is that we have indeed also identified that our levels of consumables and services are too low. And this is a gap that we will address during 2024 to increase the consumable growth, but to answer your question about the decline in Q1, it's related to SCIENION and CELLINK.
Claire, um, could you quantify the percentage contribution of sales roughly for CELLINK and SCIENION, respectively? And when should we expect them to achieve sustainable profitability? I'm trying to figure out, you know, how far you have come in the restructuring and the changes you are making there. Thank you.
Um.
In terms of weights. I don't want to go into specific weights of these individual companies, but clearly, they are substantial weights within the group. Um, and we are actively doing cost cuts and also actively strengthening the commercial organizations in both CELLINK and SCIENION. When it comes to Sonic, we have a new CEO in place since, uh, roughly a quarter. And then secondly, we have also recruited our new chief commercial officer. I won't be able to give you any guidance on when we can sort of expect to see improvements. But we are working hard on all aspects, both costs and top line in both companies.
Okay, but €1.5 million is the target cost saving. Um, sort of a timeline on that one.
It will be implemented during Q1 and Q2.
So it has gradually.
Been implemented in Q1, and it will also be implemented partially in Q2.
Okay, good. And a final question from my end. Um, so, you know, I think given the extent of the whistleblower announcement in March and the review by the Council for Swedish Financial Reporting Supervision, I am wondering if there are any other active and ongoing investigations into BICO or potential for additional impairments or similar charges. I just wanted to get that out of the way and get a comment on that. Thank you.
There are no other investigations.
Thank you for taking my questions.
Thank you.
The next question comes from Ulrich Ratner from Carnegie. Please go ahead.
Thank you very much and good morning.
A few questions on my end, and perhaps I'll start off where we left off. And on the goodwill impairment here for Q1. And sure, this is purely mechanical. You're going from ten years to five years in your estimation of goodwill. How should we view this in terms of risk going forward of additional goodwill writedowns? This although it's not a decision on your end and you haven't changed the valuation of each of the individual acquisitions. But is this to be considered more of a conservative view versus previous, you know, the goodwill that.
Surrounds the.
Short sale? Yes. Now it's a much more conservative view because what happens is you basically cut the forecast from 10 to 5 years. So instead of calculating a terminal value after ten years, you calculate it after five years. Where we believe that the companies have not reached a steady state in terms of sales and profitability. So this is indeed a much more conservative approach.
Okay, great.
Um, and again, going back to a previous question here, you mentioned gross margin potentially declining with zero acceleration due to the service business. But since this is a bit of a special segment in terms of its reporting and dynamic between gross margin and EBITDA margin, could you give us some guidance on how acceleration in biosphere will affect the EBITDA margin for the bioscience segment?
I mean, that would be giving guidance on biosphere. And as I said to Richard, we do see a strong underlying demand for lab automation. So we expect to see nice, healthy growth in biosphere during 2024. With this, you will see a diluted effect on our gross margin. Uh, given the explanation I gave to Rika, uh, that is related to biosphere having a different gross margin profile than the other companies.
Okay, let me then sort of rephrase it. Um, is biosphere and this is essentially not guidance but is biosphere reporting higher EBITDA margin versus the overall group.
Yes.
Okay. So essentially it will be margin accretive not be decritive if it accelerates.
Yeah.
Yes, yes.
Great. Um, third question I think.
That I think that's important.
I think that's important to understand that the gross margin profile in biosphere.
Zero.
Is that it's much more fully loaded than the instrument companies, and that means that the level of opex in biosphere is much less.
Yes. Yeah.
That was more or less my point. Um, and on bioprinting, um, it seems to be a bit of a struggle here for Q4 and for Q1. And how much would you attribute this to the underlying market, especially given that you're taking some cost savings related to this segment and streamlining of product offerings?
When it comes to the market. It's especially the Asian market that is affecting the sales negatively for CELLINK as well as the heavy dependence on the academic sector. And, um, the measures that we're taking for CELLINK are two-fold; one, it's ensuring that we have a focused product offering, ensuring that we're selling profitable products. And secondly, Jacob also referred to doing cost savings, and for CELLINK, it's in the range of $20 million now for the next quarter. So it's a mix of underlying market conditions where academia is still softer, and Asia is also still soft. Um, and um, the product offer. So it's a mixture of hope that answers your question.
Yes, absolutely. Automation and diagnostics have been weak markets for some time, but we're hearing from industry peers that the outlook is a bit brighter for the second half of the year. Can you give us any rough indication of current trading or when this negative trend might change?
I think it's difficult to give indications on when we will see a stop to the negative trend. Um.
We do see.
That the market is.
Picking up for our peers.
So that's a positive sign. What we are mainly focusing on at Siemian is making cost cuts to right-size the business. In addition to that, we're also significantly strengthening the commercial team.
Okay, last question on my end. Um, I know that you're currently in a strategic review, and I'm guessing you would like to reveal the highlights of this at the Capital Markets Day. I did note that you were planning something for September. Uh, just broad-based here. Um, you have invested a lot in R&D over the years. Um, do you feel that this level of investment needs to be maintained and just allocated differently, or is there a case here where you can reduce R&D based on your current product offerings, as well as within this strategic review? Does it only include keeping or focusing on your current portfolio, or also potentially divesting certain parts of your portfolio, which might not be a good strategic fit for Miko?
Mr., the strategic review is done. Uh, both, uh, in terms of the current portfolio, ensuring that the needs of our customers are addressed in the best way. And in terms of the gaps that potentially exist within the current portfolio in relation to market trends and competition, we will have to complement those gaps with either collaborations, agreements with different companies, or by developing new R&D projects. And the second part of reviewing our R&D pipeline is not only to ensure that we deploy our R&D investments in the right fields, but also to ensure a focused portfolio, whether we are to, uh, and I would presume that the review we are conducting now means that we will close some projects, but that doesn’t necessarily mean that we will invest less money, but rather invest properly in more focused and fewer projects and ensure that they are successful in terms of divesting any assets. Uh, no such decisions have been made.
Okay, great.
Just a follow-up question. Jacob, you mentioned that additional investments have been made in Siemian to expand its commercial capacities. Just some clarification. Is that related to bioconvergence or is that related to Siemian, or both?
Okay.
Great.
Um, I think overall, um, as part of the commercial excellence and driving that, that includes measures that are being done in science at SCENION with the new, uh, commercial lead. Uh, we have a new, uh, CEO also commercially driven in selling, but it's the same kind of, uh, uh, initiatives that are taking place throughout the group to ensure that we leverage our commercial abilities to a larger extent than previously made.
It's great.
And if I can just squeeze in one last question, and I know you talk about a struggling Asian market. Have you seen any positive effects from the Sartorius commercial collaboration?
When it comes to the Sartorius collaboration that was, uh, set in stone last year. Uh, we have both the commercial collaboration as well as R&D collaboration and mainly the collaboration in terms of their distributing our instruments is in Asia and Asia is being softer. So, yes, there is traction. Uh, not at the speed potentially that, uh, I think both parties would have wanted, but, um, Asia is what it is at the moment. And, uh, I don't see that it's going to remain like that. Uh. Moving on. So we see positive results from that collaboration.
Hey. Great. Uh, that was all on my end. Thank you, Maria and Jacob, and I'll get back into the queue.
Thank you.
The next question comes from Ricard and Kranz from Handelsbanken. Please go ahead.
Here, a follow-up on bioconvergence. So at the time of acquisition, CELLINK in 2021 had around, you know, a 25-plus percent EBITDA margin. Is that, uh, level where the company is performing at the moment?
Uh, yes.
Perfect. Very helpful. Thanks for taking my question.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Thank you everyone for joining us today. And thank you for all the questions. And together with Jacob, I would like to wish everyone a great Tuesday. Thank you and goodbye.



















